Department of Anesthesiology, Clinical Research Development Unit of Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.
Sub-Specialty Student in Critical Care Medicine, Department of Anesthesiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Int Immunopharmacol. 2021 Dec;101(Pt B):108241. doi: 10.1016/j.intimp.2021.108241. Epub 2021 Oct 15.
IFNβs are known as one of the most promising drugs used for COVID-19 treatment. This study aimed to investigate the effects of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) on COVID-19 inpatients.
In this study, we retrospectively evaluated the clinical treatment outcomes of 100 patients with COVID-19 who received IFN-β 1-a and IFN-β 1-b during their hospitalization period. The rate of discharge from the hospital was considered equal to the clinical improvement and then evaluated as a primary outcome. Moreover, mortality, ICU admission and length of ICU stay, frequency of intubation and use of mechanical ventilation, duration of hospitalization, laboratory factors, and medications were assessed as secondary outcomes.
The median discharge time of IFN-β 1a recipients was approximately equal to that of IFN-β 1-b recipients as 9 (5-10) days and 7 (5-11) days, respectively (HR = 2.43, P = 0.75). Mortality rate was also estimated as 10% among IFN-β 1-a recipients and 14% among IFN-β 1-b recipients, which was not statistically significant (p = 0.190). ICU hospitalization rate for the IFN-β 1-a recipients and IFN-β 1-b recipients was 26% and 36%, respectively. In addition, no significant difference was found between these two intervention groups in terms of ICU length of stay (1 (0-2) vs. 1 (0-4.25(, respectively,) P = 0.357). There was no significant difference between the two study groups in terms of frequency of mechanical ventilation and length of hospital stay.
There was no significant difference between the two groups in terms of shortening the disease time, clinical improvements and other outcomes.
干扰素β（IFNβ）被认为是治疗 COVID-19 最有希望的药物之一。本研究旨在探讨 IFN-β1-a（干扰素β-1a）和 IFN-β1-b（干扰素β-1b）治疗 COVID-19 住院患者的效果。
本研究回顾性评估了 100 例 COVID-19 住院患者在住院期间接受 IFN-β1-a 和 IFN-β1-b 治疗的临床治疗结局。出院率被认为等同于临床改善，并作为主要结局进行评估。此外，死亡率、入住 ICU、ICU 入住时间、插管频率和机械通气使用、住院时间、实验室因素和药物使用被评估为次要结局。
IFN-β1-a 组和 IFN-β1-b 组的中位出院时间分别约为 9（5-10）天和 7（5-11）天（HR=2.43，P=0.75）。IFN-β1-a 组的死亡率为 10%，IFN-β1-b 组的死亡率为 14%，差异无统计学意义（p=0.190）。IFN-β1-a 组和 IFN-β1-b 组的 ICU 住院率分别为 26%和 36%。此外，两组间 ICU 住院时间（1（0-2）vs. 1（0-4.25），P=0.357）无显著差异。两组间机械通气频率和住院时间无显著差异。
两组在缩短疾病时间、临床改善和其他结局方面无显著差异。
